VERASTEM, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.4 USD | -5.98% |
|
-3.29% | +40.79% |
| May. 09 | Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 18 | Verastem Names John Hayslip as Chief Medical Officer | MT |
Presenter SpeechBrian Stuglik (Executives)Good morning, and welcome. Thank you for being with ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Companyâs advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).
Calendar
2024-05-22
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.13
USD
Average target price
28.79
USD
Spread / Average Target
+137.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.79% | 307M | |
| +9.44% | 114B | |
| +11.55% | 104B | |
| -13.93% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.03% | 17.89B | |
| +7.03% | 14.28B | |
| +35.48% | 12.55B |
- Stock Market
- Equities
- VSTM Stock
- News Verastem, Inc.
- Transcript : Verastem, Inc. - Shareholder/Analyst Call
